Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial-Reference-Cited by-同舟云学术

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Published:2019-05-13 Issue:6 Volume:25 Page:920-928
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Voorwerk Leonie,Slagter Maarten,Horlings Hugo M.^ORCID,Sikorska Karolina,van de Vijver Koen K.^ORCID,de Maaker Michiel,Nederlof Iris,Kluin Roelof J. C.,Warren Sarah,Ong SuFey,Wiersma Terry G.,Russell Nicola S.^ORCID,Lalezari Ferry,Schouten Philip C.,Bakker Noor A. M.,Ketelaars Steven L. C.,Peters Dennis,Lange Charlotte A. H.,van Werkhoven Erik^ORCID,van Tinteren Harm,Mandjes Ingrid A. M.,Kemper Inge,Onderwater Suzanne,Chalabi Myriam,Wilgenhof Sofie,Haanen John B. A. G.^ORCID,Salgado Roberto,de Visser Karin E.^ORCID,Sonke Gabe S.,Wessels Lodewyk F. A.,Linn Sabine C.,Schumacher Ton N.^ORCID,Blank Christian U.,Kok Marleen^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0432-4.pdf

Reference60 articles.

1. Adams, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase 2 KEYNOTE-086 study. Ann. Oncol. https://doi.org/10.1093/annonc/mdy517 (2018).

2. Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460–2467 (2016).

3. Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5, 74–82 (2018).

4. Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res. Treat. 167, 671–686 (2018).

5. Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 380, 987–988 (2018).

Cited by 643 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically engineered CD276-anchoring biomimetic nanovesicles target senescent escaped tumor cells to overcome chemoresistant and immunosuppressive breast cancer;Biomaterials;2025-02

2. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

3. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

4. Research trends on nanomaterials in triple negative breast cancer (TNBC): a bibliometric analysis from 2010 to 2024;Drug Delivery and Translational Research;2024-09-06

5. Cobalt(III) prodrug-based nanomedicine for inducing immunogenic cell death and enhancing chemo-immunotherapy;Journal of Controlled Release;2024-09